Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes.
Cardiovascular disease
Lower-limb amputation
Mortality
Myocardial infarction
Stroke
Type 1 diabetes mellitus
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
09 05 2022
09 05 2022
Historique:
received:
03
02
2022
accepted:
28
02
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
Cardiovascular disease (CVD) and nontraumatic lower-limb amputation (LLA) each results in reduced life expectancy in patients with type 1 diabetes, but the differential burden between these conditions is unknown. We compared the effects of CVD and LLA on the risk of mortality in people with type 1 diabetes. We used pooled data from the SURGENE, GENEDIAB, and GENESIS prospective cohorts. Data were divided into: 1/absence of CVD (myocardial infarction and/or stroke) nor LLA, 2/history of CVD alone without LLA, 3/LLA alone without CVD or 4/both conditions at baseline. Participants with baseline history of peripheral artery disease were excluded from groups 1 and 2. The study endpoint was any death occurring during follow-up, regardless of the causes. Among 1169 participants (male 55%, age 40 ± 13 years, diabetes duration 23 ± 11 years), CVD, LLA or both were present at baseline in 49 (4.2%), 62 (5.3%) and 20 (1.7%) subjects, respectively. All-cause death occurred in 304 (26%) participants during 17-year follow-up, corresponding to 18,426 person-years and an incidence rate of 16 (95%CI, 15-18) per 1000 person-years. The risk of death increased in individuals with baseline history of CVD (adjusted HR 2.00 [95% CI 1.34-3.01], p = 0.0008) or LLA (2.26 [1.56-3.28], p < 0.0001), versus no condition, with an additive effect in people with both conditions (5.32 [3.14-9.00], p < 0.0001). No incremental risk of death was observed in people with CVD versus LLA (0.87 [0.54-1.41]). Compared with no condition, CVD and LLA were similarly associated with reduced life expectancy during follow-up: 2.79 (95% CI 1.26-4.32) and 3.38 (1.87-4.88) years, respectively. Combined conditions expose to 7.04 (4.76-9.31) less years of life expectancy (all p < 0.0001). CVD and LLA conferred a similar burden regarding mortality in type 1 diabetes population. Our findings encourage a careful consideration of people with type 1 diabetes and LLA as usually recommended for those with CVD, in terms of management of risk factors, treatments and prevention.
Sections du résumé
BACKGROUND
Cardiovascular disease (CVD) and nontraumatic lower-limb amputation (LLA) each results in reduced life expectancy in patients with type 1 diabetes, but the differential burden between these conditions is unknown. We compared the effects of CVD and LLA on the risk of mortality in people with type 1 diabetes.
METHODS
We used pooled data from the SURGENE, GENEDIAB, and GENESIS prospective cohorts. Data were divided into: 1/absence of CVD (myocardial infarction and/or stroke) nor LLA, 2/history of CVD alone without LLA, 3/LLA alone without CVD or 4/both conditions at baseline. Participants with baseline history of peripheral artery disease were excluded from groups 1 and 2. The study endpoint was any death occurring during follow-up, regardless of the causes.
RESULTS
Among 1169 participants (male 55%, age 40 ± 13 years, diabetes duration 23 ± 11 years), CVD, LLA or both were present at baseline in 49 (4.2%), 62 (5.3%) and 20 (1.7%) subjects, respectively. All-cause death occurred in 304 (26%) participants during 17-year follow-up, corresponding to 18,426 person-years and an incidence rate of 16 (95%CI, 15-18) per 1000 person-years. The risk of death increased in individuals with baseline history of CVD (adjusted HR 2.00 [95% CI 1.34-3.01], p = 0.0008) or LLA (2.26 [1.56-3.28], p < 0.0001), versus no condition, with an additive effect in people with both conditions (5.32 [3.14-9.00], p < 0.0001). No incremental risk of death was observed in people with CVD versus LLA (0.87 [0.54-1.41]). Compared with no condition, CVD and LLA were similarly associated with reduced life expectancy during follow-up: 2.79 (95% CI 1.26-4.32) and 3.38 (1.87-4.88) years, respectively. Combined conditions expose to 7.04 (4.76-9.31) less years of life expectancy (all p < 0.0001).
CONCLUSIONS
CVD and LLA conferred a similar burden regarding mortality in type 1 diabetes population. Our findings encourage a careful consideration of people with type 1 diabetes and LLA as usually recommended for those with CVD, in terms of management of risk factors, treatments and prevention.
Identifiants
pubmed: 35534880
doi: 10.1186/s12933-022-01487-8
pii: 10.1186/s12933-022-01487-8
pmc: PMC9088124
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Informations de copyright
© 2022. The Author(s).
Références
Arch Cardiovasc Dis. 2015 Apr;108(4):227-34
pubmed: 25682547
Diabetes Care. 2018 Oct;41(10):2162-2169
pubmed: 30072406
Diabetologia. 2018 Apr;61(4):977-984
pubmed: 29185011
J Foot Ankle Surg. 2016 May-Jun;55(3):591-9
pubmed: 26898398
Cardiovasc Diabetol. 2015 Jan 15;14:845
pubmed: 25855220
Lancet. 2005 Nov 12;366(9498):1719-24
pubmed: 16291066
Diabetes Care. 2004 Nov;27(11):2661-8
pubmed: 15505002
Diabetes. 2009 Jul;58(7):1651-8
pubmed: 19401416
PLoS One. 2014 May 12;9(5):e96916
pubmed: 24819633
Diabetes Care. 2006 Oct;29(10):2252-6
pubmed: 17003302
Diabetologia. 2016 Jun;59(6):1177-85
pubmed: 26796634
Diabetologia. 2021 Dec;64(12):2751-2761
pubmed: 34494137
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
Lancet. 2019 Mar 9;393(10175):985
pubmed: 30860050
JAMA. 2015 Jan 6;313(1):37-44
pubmed: 25562264
BMJ Open Diabetes Res Care. 2020 Jul;8(1):
pubmed: 32690575
N Engl J Med. 2017 Jun 15;376(24):2367-2375
pubmed: 28614678
Diabetes Care. 2021 Aug;44(8):1885-1893
pubmed: 34162664
Diabetes Care. 2016 Jun;39(6):1018-26
pubmed: 27208325
Circulation. 2019 Aug 6;140(6):449-458
pubmed: 31280589
Diabetologia. 2009 Apr;52(4):705-14
pubmed: 19183936
Diabetes Care. 2020 May;43(5):964-974
pubmed: 32139380
Stat Med. 2013 Dec 30;32(30):5278-85
pubmed: 23839860
Diabet Med. 2019 Aug;36(8):995-1002
pubmed: 31004370
Lancet Diabetes Endocrinol. 2021 Sep;9(9):575-585
pubmed: 34303414
Circulation. 2019 Feb 5;139(6):730-743
pubmed: 30586738
Cardiovasc Diabetol. 2017 Jul 27;16(1):95
pubmed: 28750645
Diabetes Care. 2020 Apr;43(4):828-834
pubmed: 31988064
Cardiovasc Diabetol. 2016 Jan 07;15:5
pubmed: 26743116
Diabetes Care. 2011 Jun;34(6):1350-4
pubmed: 21540432
Lancet. 2018 Aug 11;392(10146):477-486
pubmed: 30129464
J Clin Invest. 1997 Apr 1;99(7):1585-95
pubmed: 9120002
Circ Res. 2010 Oct 29;107(9):1058-70
pubmed: 21030723
Diabetes Care. 2015 Feb;38(2):316-22
pubmed: 25492401
BMJ Open Diabetes Res Care. 2019 Apr 14;7(1):e000602
pubmed: 31114696
Diabetes Care. 2022 Feb 1;45(2):407-415
pubmed: 34853028
J Am Soc Nephrol. 2001 Mar;12(3):541-549
pubmed: 11181802
Cardiovasc Diabetol. 2021 Jan 4;20(1):3
pubmed: 33397352
Metabolism. 2016 Feb;65(2):12-9
pubmed: 26773925
Diabetes Care. 2010 Apr;33(4):878-80
pubmed: 20067975